SCHEMBL23304101

SCHEMBL23304101

Nc1nnc(Cl)cc1N1CC2CCC(C1)N2c1cccc(CO)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 2/20 0.43
▸ SMARCA4 P51532 2/20 0.43
▸ OPRM1 P35372 10/20 0.41
▸ OPRD1 P41143 3/20 0.38
▸ OPRK1 P41145 3/20 0.38
▸ ADRA2A P08913 1/20 0.36
▸ AR P10275 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ SCN5A Q14524 1/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ ABL2 P42684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29910569 1.00 SMARCA2 (0.43) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL29910687 0.85 OPRM1 (0.52) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL30796186 0.85 OPRM1 (0.52) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL23303143 0.85 OPRM1 (0.52) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL27456634 0.85 OPRM1 (0.52) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL27456475 0.81 OPRM1 (0.47) SMARCA2SMARCA4OPRM1OPRD1OPRK1
SCHEMBL29910555 0.80 SMARCA2 (0.41) SMARCA2SMARCA4OPRM1
SCHEMBL23304039 0.80 SMARCA2 (0.41) SMARCA2SMARCA4OPRM1
SCHEMBL23301218 0.79 KDM4E (0.43) SMARCA2SMARCA4OPRM1
SCHEMBL29942586 0.79 KDM4E (0.43) SMARCA2SMARCA4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS C4 THERAPEUTICS, INC. 2023-01-05 — — US disclosed
EP-4054724-A1 BIFUNCTIONAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2022-09-14 — — EP disclosed
WO-2021086785-A1 BIFUNCTIONAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS ITCH, EGFR, MUC1 SMARCA2 3260/4885SMARCA4 3599/4885OPRM1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback